Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Mark R. Olsen"'
Autor:
Bradley Curtis Carthon, Jesus Zoco, Thomas E. Hutson, Mark R. Olsen, Edward Arrowsmith, Johanna C. Bendell, Hamid Emamekhoo, Joshua Zhang, Daniel J. George, Scott S. Tykodi, David Leung, Ana M. Molina, Alexandra Drakaki, Lucio N. Gordan, Ivor John Percent, Daniel C. Cho, Jennifer L. Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Cancer. 128:966-974
Background Nivolumab plus ipilimumab (NIVO + IPI) has demonstrated long-term efficacy and safety in patients with previously untreated, advanced renal cell carcinoma (aRCC). Although most phase 3 clinical trials exclude patients with brain metastases
Autor:
Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit K. Jain, Bradley Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana Molina, Gurjyot Doshi, Brian Lingerfelt, Ralph J. Hauke, Vijay Gunuganti, Ian Schnadig, Peter Van Veldhuizen, Mark Fleming, Robert Galamaga, Mukul Gupta, Hugo Hool, Thomas Hutson, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Scott S. Tykodi
Publikováno v:
Clinical genitourinary cancer. 18(6)
Background The open-label, phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab monotherapy 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma
Autor:
Joshua J. McFarlane, Mark D. Kochenderfer, Mark R. Olsen, Todd M. Bauer, Ana Molina, Ralph J. Hauke, James A. Reeves, Sunil Babu, Peter Van Veldhuizen, Bradley Somer, Vijay Gunuganti, Ian Schnadig, Saby George, Ray D. Page, Edward Arrowsmith, Rohit K. Jain, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Nicholas J. Vogelzang
Publikováno v:
Clinical genitourinary cancer. 18(6)
The open-label, phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab monotherapy 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma (RCC). Thre
Autor:
Coleman K. Obasaju, Ramaswamy Govindan, Shi Li, Jingyi Liu, Eduardo J. Pennella, David R. Spigel, Mark A. Socinski, Edward B. Garon, Jyoti D. Patel, Mark R. Olsen, Robert C. Hermann, Susan C. Guba, Craig H. Reynolds, Philip Bonomi
Publikováno v:
Clinical Lung Cancer. 16:200-208
Introduction African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. pac
Autor:
Jyoti D. Patel, Jian Chen, Jingyi Liu, Edward B. Garon, Robert C. Hermann, Katherine B. Winfree, Mark A. Socinski, Susan C. Guba, Mark R. Olsen, Ramaswamy Govindan, Craig H. Reynolds, Philip Bonomi, David R. Spigel
Publikováno v:
Journal of Thoracic Oncology. 10(2):353-359
IntroductionTreatment impact on quality of life (QoL) informs treatment management decisions in advanced nonsquamous non–small-cell lung cancer (NS NSCLC). QoL outcomes from the phase III PointBreak trial are reported.MethodsChemonaive patients (n
Autor:
Mark R. Olsen, Thomas E. Hutson, Jennifer L. Johansen, Daniel C. Cho, Johanna C. Bendell, Ana M. Molina, Scott S. Tykodi, Bradley C. Carthon, Richard Lee, Tina C. Young, Hamid Emamekhoo, Lucio N. Gordan, Alexandra Drakaki, Daniel J. George, Arash Rezazadeh Kalebasty, Ivor John Percent
Publikováno v:
Journal of Clinical Oncology. 37:4517-4517
4517 Background: Previous clinical trials of patients (pts) with aRCC, including CheckMate 214, have mostly excluded pts with brain metastases. However, antitumor activity in pts with brain metastases has been observed in pts with melanoma treated wi
Autor:
Mark R. Olsen, Philip Bonomi, Joseph Mace, Hagop Youssoufian, Romeo A. Mandanas, Terry L. Katz, Myo Min, Hyun Jung Lee, Grishma Sheth
Publikováno v:
Journal of Thoracic Oncology. 8:338-345
Introduction We conducted a phase II study of dual-agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with paclitaxel and carboplatin chemotherapy in non–small-cell lung cancer. Methods Patients with stage IIIB
Autor:
Olga Valota, Gary R. Hudes, Mark R. Olsen, John A. Thompson, Thomas E. Hutson, Robert J. Motzer, Robert A. Figlin, John M. Burke, Subramanian Hariharan, George Wilding, Akintunde Bello, David Cella, Neeraj Agarwal, Bridget Martell, Jinyu Yuan, Beata Korytowsky, William Jeffery Edenfield
Publikováno v:
Journal of Clinical Oncology. 30:1371-1377
Purpose Sunitinib has shown antitumor activity with a manageable safety profile as metastatic renal cell carcinoma (RCC) treatment, when given by the standard intermittent schedule as well as a continuous daily dosing (CDD) schedule. A trial was cond
Autor:
Jingyi Liu, Eduardo J. Pennella, Mark R. Olsen, Philip Bonomi, Coleman K. Obasaju, Mark A. Socinski, David R. Spigel, Robert C. Hermann, Susan C. Guba, Bente Frimodt-Moller, Jyoti D. Patel, William J. John, Edward B. Garon, Thaddeus Beck, Craig H. Reynolds, Ramaswamy Govindan, Robert M. Jotte, Donald A. Richards
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(34)
Purpose PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed pl
Publikováno v:
Journal of Organometallic Chemistry. 579:243-251
Two novel types of cyclometallated rings are described. Orthomanganation of Ph3PNPh gave Ph2P[ NPh]C 6 H 4 M n(CO)4, 5a, containing an N,C-chelated five-membered ring, characterised by single crystal X-ray determinations of two distinct polymor